Biomarker testing is important for determining the the best treatment for patients newly diagnosed with NSCLC. touchONCOLOGY spoke to Professor Fred Hirsch (The Mount Sinai Hospital, New York City, NY, USA) to discuss his presentation at the European Lung Cancer Summit 2022, providing an update on the current state of personalized medicine and molecular testing in lung cancer.
Question: Which NSCLC patients should undergo biomarker testing?
Speaker Disclosure: Fred Hirsch is a member of the advisory board for: Amgen, AstraZeneca/Daiichi,Bristol-Myers, Novartis, NextCure, Novocure, Nectin Therapeutics, Sanofi/Regeneron and OncoCyteSquibb.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the European Lung Cancer Summit 2022
Share this Video
Related Videos In Lung Cancer
Misako Nagasaka, ELCS 2022: Results of the TRUST-II Study
touchONCOLOGY spoke to Prof Misako Nagasaka (University of California Irvine, Detroit, MI, USA) to discuss her presentation at the European Lung Cancer Summit 2022, providing the results of the TRUST-II study, a global phase II study for taletrectinib in ROS1 fusion positive lung cancer and other solid tumours. Questions What is taletrectinib […]
Niels Reinmuth, ELCS 2022: Characteristics of Long-term Survivors in the CASPIAN Study
The CASPIAN study evaluated the efficacy and safety of durvalumab plus tremelimumab and platinum-etoposide extensive-stage SCLC. touchONCOLOGY spoke to Niels Reinmuth (Munich, Germany) to discuss the characteristics of long-term survivors in the CASPIAN study. Clinical Trial Identification: NCT03043872 Questions What did the CASPIAN study teach us about the efficacy and safety of […]
Prasad S Adusumilli, ELCS 2022: Potential of CAR-T Therapy in Lung Cancer
There is still extensive ongoing research, however CAR-T technology for lung cancer is providing much promise but many challenges. touchONCOLOGY spoke to Dr Prasad S Adusumilli (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) to discuss the potential of CAR-T therapy in lung cancer and the recent breakthroughs in this area. Questions […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!